Amplifyer Bio Publishes Liquid Biopsy Preclinical Data on Showing up to 100-Fold Increase in ctDNA Recovery
September 21, 2026
CAMBRIDGE, Mass., September 22, 2026 — Amplifyer Bio, a biotech company unleashing the power of liquid biopsies, today announced preclinical data showing that a humanized priming agent achieved up to a 100-fold increase in circulating tumor DNA (ctDNA) recovery.
“Liquid biopsy tests offer a far less invasive and costly approach to detecting cancer, but currently the effectiveness of liquid biopsies is limited due to the human body quickly removing circulating tumor DNA from the bloodstream before it can be measured,” said Annie Murphy, CEO at Amplifyer Bio. “Our approach is designed to recover more cell-free DNA input per blood draw, which has the potential to make liquid biopsies far more widespread and clinically actionable.”
Amplifyer has raised $7 million in seed funding led by Pillar VC to improve liquid biopsies through boosting ctDNA yield with humanized priming agents. At 2026 ctDNA International Symposium, Amplifyer shared significant milestones from designing and screening 74 humanized DNA-binding antibodies. Highlights include:
About Amplifyer Bio
Amplifyer Bio, Inc. is developing technology of transformative potential for the liquid biopsy field. The company is focused on the development of novel priming agents that sit upstream of liquid biopsy diagnostics, improving test performance. Amplifyer Bio’s first program will be focused on increasing cfDNA in blood for cancer diagnostics. This will provide both physicians and patients higher quantity and quality of genomic information related to their cancer, with the aim of improving clinical outcomes. Amplifyer Bio was spun out of MIT and the Broad Institute, building on work from the labs of Dr. Sangeeta Bhatia, Dr. Chris Love and Dr. Viktor Adalsteinsson.
To learn more, visit amplifyer.bio.
“Liquid biopsy tests offer a far less invasive and costly approach to detecting cancer, but currently the effectiveness of liquid biopsies is limited due to the human body quickly removing circulating tumor DNA from the bloodstream before it can be measured,” said Annie Murphy, CEO at Amplifyer Bio. “Our approach is designed to recover more cell-free DNA input per blood draw, which has the potential to make liquid biopsies far more widespread and clinically actionable.”
Amplifyer has raised $7 million in seed funding led by Pillar VC to improve liquid biopsies through boosting ctDNA yield with humanized priming agents. At 2026 ctDNA International Symposium, Amplifyer shared significant milestones from designing and screening 74 humanized DNA-binding antibodies. Highlights include:
- Multiple humanized candidates outperformed the academic antibody, achieving greater than 20-fold increases in ctDNA recovery two hours after administration.
- A humanized candidate achieved up to 100-fold recovery in ctDNA.
- Priming produced significantly better sensitivity for cancer detection with a 16-probe panel and more comprehensive molecular profiling.
- cfDNA binding is tumor-agnostic and confirmed across a diverse set of human cancer cell lines.
- Whole-genome sequencing confirmed that some candidates preserved cfDNA fragmentomic features and did not introduce GC bias.
About Amplifyer Bio
Amplifyer Bio, Inc. is developing technology of transformative potential for the liquid biopsy field. The company is focused on the development of novel priming agents that sit upstream of liquid biopsy diagnostics, improving test performance. Amplifyer Bio’s first program will be focused on increasing cfDNA in blood for cancer diagnostics. This will provide both physicians and patients higher quantity and quality of genomic information related to their cancer, with the aim of improving clinical outcomes. Amplifyer Bio was spun out of MIT and the Broad Institute, building on work from the labs of Dr. Sangeeta Bhatia, Dr. Chris Love and Dr. Viktor Adalsteinsson.
To learn more, visit amplifyer.bio.